Bone Medical gets approval for human clinical study

THE ROADHOUSE PHARMACY: Bone Medical Ltd (ASX: BNE) has received approval to proceed with a planned human clinical study, the company announced to the Australian Securities Exchange in April 2014.

Bone Medical said the study will compare the company’s potential oral treatment for osteoporosis against a commercially available injectable osteoporosis treatment.

The study has been reviewed and approved by the Human Research Ethical Committee at the QIMR Berghofer Medical Research Institute in Brisbane, where the study is to be conducted.

Bone Medical expects the study to commence before the end of May and is anticipated to be concluded within three months.

“One of our goals when recapitalising the company in January 2014 was to advance the company’s technology and so we are very pleased that it has taken only four months to recommence the clinical studies of Bone’s orally delivered PTH,” Bone Medical chairman said in the company’s announcement to the ASX.

Bone Medical also announced that Peter Young has stepped down as CEO and director of the Company and will now be acting in a role as senior consultant and advisor.

In this capacity, Bone Medical said Young will continue to provide ongoing operational support and strategic advice to assist the company while maintaining effective continuity going forward.

Website: www.bone-ltd.com

Cellmid selects lead antibody for clinical trials

THE ROADHOUSE PHARMACY: Cellmid Limited (ASX: CDY) has completed
humanisation, testing and selection of its lead anti-midkine (MK)
antibody for the company’s planned ‘first in class’ clinical trials in
oncology.

The company said this was a major step in advancing towards clinical studies and keeps it on track with the development program outlined to the market earlier in 2014.

Cellmid claims the lead antibody, designated CAB102, has been shown to greatly reduce chemotherapy resistance in a preclinical model of lung cancer in combination with carboplatin.

In addition to its functional activity in vivo, it has produced strong in vitro functionality in specifically designed MK migration assays.

Initial cell expression and stability data has confirmed it can be manufactured commercially, making it a feasible drug product.

“With the completion of lead selection, and after a well-planned and extensive testing program, our preparations for clinical trials are well on track,” Cellmid chief executive officer Maria Halasz said in the company’s announcement to the Australian Securities Exchange.

Website: www.cellmid.com.au

Admedus receives first U.S. orders

THE ROADHOUSE PHARMACY: Admedus (ASX: AHZ) has received the first sales orders for the company’s CardioCel® product in the US market.

The company said the initial US sales orders have come ahead of its expected mid-year timing.
“This is an important milestone for the company as we look to grow our revenue over the coming twelve months and beyond,” Admedus chief executive officer Lee Rodne said in the company’s announcement to the Australian Securities Exchange.

“We are aiming for CardioCel® to be in use in 15 key centres in Europe and the US over the next 12 months, which will provide us with a significant presence in the market.”

The first sales orders for CardioCel® in the US market follow a presentation by Admedus to US cardio-thoracic surgeons during the recent American Association of Thoracic Surgeons (AATS) conference in Toronto.

In Europe, Admedus officially launched CardioCel® late in 2013, with the aim of introducing it into 15 key cardio-thoracic centres.

To date, CardioCel® has been used in eight of the target centres in Europe and the company indicated it expects several more to come on stream by mid-year.

Admedus claims surgeons who have used CardioCel® in surgical procedures have not reported any issues.

CardioCel® continues to be used in Australia under the Authorised Prescriber Scheme with over 100 patients implanted.

Email: info@admedus.com.au

Website: www.admedus.com

RIU Sydney Round-up 2014

THE CONFERENCE CALLER: Next week the Australian mining sector will gather in Sydney for the eleventh annual RIU Sydney Resources Round-Up.

The three day conference is being held at the Sofitel Sydney Wentworth Hotel and is set to provide the investment community with opportunities to meet the people behind some of Australia’s leading exploration and mid-tier mining companies.

“Brokers and investors from all over Australia come to see and hear first-hand from the companies what progress has been made and what their strategies will be for the next 12 months and beyond,” Stewart McDonald, managing director of conference organiser Vertical Events said.

“The highly attended auditorium provides the perfect outlet for resources executives to present their latest exploration and mining developments.”

The conference schedule is full to the brim with 36 companies sharing the bill with a number of keynote speakers, including Lion Selection Group executive director Hedley Widdup, who provided us with some insight to his presentation.

“2012 and 2013 were like a death of 1000 cuts for junior miners, as the availability of capital and their valuations both went through a persistent decline,” Widdup told The Resources Roadhouse.

“Price is proportional to liquidity – one will not recover without the other.

“The conditions of mid 2013 showed many signs of being the lowest ebb of liquidity.

“A return to boom conditions is likely to be slow, previous cycles have all been this way, but nevertheless it appears the worst is behind us.”

Another presentation that is sure to attract a crowd will be the one titled, ‘Where are the Opportunities?’ that from Breakaway Research senior research analyst Mark Gordon.

Gordon told The Roadhouse he expects to be covering is a brief history of the recent boom, a view of where the industry is currently at, and possibly heading, then looking at where investment opportunities are at and what to look for in assessing them.

“We have now entered a period of consolidation following the end of the resources ‘super-cycle’, which commenced in 2003 and was driven largely by China,” Gordon said.

“Despite the recent falls in resources, we still see plenty of opportunities in the sector, however quality is now the keyword, with the speculation and euphoria of the boom well behind us.

“Investment selection will require judicious due diligence, with critical factors to be assessed including quality of management and projects.”

 

Cassini bags BHP bundle

THE INSIDE STORY: Junior exploration play Cassini Resources (ASX: CZI) recently caused a minor tremor on the boards of the Australian Securities Exchange.

The excitement followed the company’s announcement it had executed a Sale and Purchase Agreement to acquire 100 per cent of the West Musgrave project in Western Australia.

While the acquisition of such a project by a junior company is fairly common, what cast this particular deal into the spotlight was the identity of the vendor.

Cassini secured the property from BHP Billiton Nickel West and BHP Billiton Minerals, two subsidiaries of global mining powerhouse BHP Billiton (ASX: BHP).

The West Musgrave project contains the Nebo and Babel sister deposits, commonly referred to as Nebo‐Babel, the Succoth copper exploration prospect plus a number of prospective exploration targets.

 

The crucial element of the deal for Cassini is all these deposits and targets come under the company’s control with a great deal of exploration and development work already completed.

Nebo‐Babel, the project’s pivotal prospect, was first discovered by Western Mining Corporation (WMC) in 2000, when drilling intersected mineralisation of 26.55 metres at 2.45 per cent nickel, 1.78 per cent copper, 0.74 grams per tonne platinum group elements (PGE) plus gold.

BHP arrived on the scene by swallowing up WMC in 2005, after which time Nebo‐Babel was subjected to a healthy amount of exploration activity, which mainly focused on developing the deposits as a large‐scale, low‐grade production model.

Nebo‐Babel currently has an Inferred resource 446 million tonnes at 0.33 per cent nickel and 0.35 per cent copper (0.2 per cent nickel cut‐off) for 1.47 million tonnes of contained nickel and 1.56 million tonnes of contained copper.

“Because of the way BHP originally approached the project, the high-grade ore body within the deposits was never really domained,” Cassini Resources managing director Richard Bevan told The Resources Roadhouse.

“They intended it to become a large large‐scale, low‐grade production model.

“We intend looking at the project differently, as a high-grade opportunity – as a smaller project than what BHP originally envisaged.

 “So we have some work to do over the next six to twelve months to really get in there and define that high-grade ore body.”

Cassini is confident Nebo‐Babel has the characteristics necessary for it to become a smaller, higher‐grade operation.

This confidence stems from the results of the due diligence the company carried out over the deposit, which revealed its substantial production potential.

Cassini’s due diligence demonstrated the existence of discrete higher‐grade zones within the Nebo‐Babel deposit, which have yet to be fully delineated by drilling.

Both deposits are suitable for openpit co‐development as they are very close to the surface, with the Babel deposit outcropping.

Nebo‐Babel also revealed favourable ore‐body geometry as a flat dipping deposit, which Cassini considers shows potential for an openpit operation with a very low stripping ratio.

Another vital aspect of the acquisition is the reasonably small consideration of $250,000, ten per cent of which has already been paid by Cassini as a deposit.

BHP will be paid a two per cent net smelter royalty, which will apply to the net proceeds from future production from the tenements within the project.

Cassini will also pay a production milestone payment due 12 months after production from the project commences, amounting to $10million in cash.

Cassini considers such a minimal up-front cost de‐risks the project considerably and allows it to focus on assessing future development options.

“It is better than drilling the discovery hole in many ways,” Bevan said.

“BHP has spent a significant amount of money on the deposit to bring it to where it is now, which means we don’t have to.

“For us that means we are moved a considerable way along – a lot of the risk is gone – in the sense that we are not out there trying to find something – it’s already been found.

“For the cost of a drill program [the $250,000 consideration] we have got a project with high-probability for an economic deposit.

“However, there are a couple of things we need to do in order to confirm that is the case.”

 

Using what it has learned from the extensive work already undertaken on the project, and the $10 million proceeds from a subsequent share placement, Cassini proposes carrying out resource definition drilling to infill known higher‐grade zones to build a higher‐grade subset to the overall Nebo ‐ Babel Mineral Resource.

It will also conduct metallurgical testing to ensure it can achieve acceptable recoveries within higher‐grade ore at Nebo‐Babel.

“BHP has already conducted a fair bit of metallurgy testing,” Bevan explained.

“However, they approached that in a similar way to which they approached the project itself – by taking bulk composite samples.

“They didn’t actually look at the recoveries for the higher grade, or the recovery for the different types of ore present.

“That’s the work that needs to be done. That’s the opportunity for us – to approach it as a junior company would – and within that greater project area is a smaller valuable subset.”

Cassini’s acquisition of the West Musgrave project demonstrates that, even though the market may currently be experiencing some tough times, when a junior mining company is prepared to take a chance it can still be handsomely rewarded.

The overnight success of the deal started some 18 months ago when Cassini boldly approached BHP to gauge whether it may be interested in divesting the projects. As it turned out BHP was interested.

There was also a great deal of interest in the projects from a number of Cassini’s contemporaries in the junior sphere, all of which were just as eager to augment their own projects in the West Musgrave region.

“One of the criteria BHP had was that the project would go to a company with existing relationships in the area and would develop the project so the communities in the region would actually see some benefit from the project,” Bevan said.
 
“Fortunately we have worked hard developing an existing relationship with the communities and the traditional owners in the region.”

Another differentiating factor that shouldn’t be overlooked is the personnel who sit around Cassini’s Boardroom table.

The company’s chairman Mike Young with his exploration to production experience with BC Iron, demonstrates the ability to take an asset and bring it through to production in a reasonably short time frame.

John Hronsky has been consulting to Cassini through his consulting group Western Mining Services and was previously with BHP Billiton Minerals Exploration and WMC Resources.

He was a key member of the targeting strategy and exploration team that led to the discovery of Nebo‐ Babel, which does qualify him to be a very handy man for Cassini to have on its team at this time.

“We consider the West Musgrave project to be a truly significant set of assets, and being able to acquire them is a great result for Cassini,” Bevan said.

“Nebo‐Babel is widely regarded as a world‐class deposit and, as a smaller company, we look forward to applying a different, innovative approach to these assets, focussing on higher‐grade opportunities, with the aim of progressing their development to production as a priority.

“We are confident we can hit a number of major project milestones within the next six to twelve months.”


Cassini Resources Limited (CZI)
…The Short Story

HEAD OFFICE
945 Wellington Street
West Perth WA 6005

Phone: +61 8 9322 7600
Fax: + 61 8 9322 7602

Email: admin@cassiniresources.com.au
Web: www.cassiniresources.com.au

DIRECTORS and MANAGEMENT
Mike Young, Richard Bevan, David Johnson, Dr Jon Hronsky, Phil Warren, Greg Miles

MAJOR SHAREHOLDERS
Directors         12.2%
Cornela Pty Ltd     5.5%

Top 40        49.6%

 

Gold Road grinds out higher recoveries at Gruyere

THE DRILL SERGEANT: Gold Road Resources (ASX: GOR) has received results of additional metallurgical testwork the company had conducted in response to recommendations made in a metallurgical report released in February.

 

Gruyere plan projection illustrating location of RC holes sampled
for Metallurgical testing composites. Source: Company announcement

 

The latest metallurgical testing has used a coarser grind size on samples from the company’s Gruyere gold project in Western Australia to produce recoveries in excess of 95 per cent at P80s of 106 micron and 125 micron with air sparging.

Using oxygen sparging increased leach kinetics and improved recovery by an additional one per cent to two percent.

Intermittent bottle roll tests simulating heap leach recovery produced rapid gold extraction of 70.3 per cent in 24 hours, levelling out at 81.2 per cent after 96 hours.

Gold Road indicated using a coarser grind size could result in lower capital and operating costs for the grinding circuit in any potential future processing plant as it would enable the company to reduce power consumption and increased throughput potential.

It also identified oxygen sparging as a potential method as it too could allow for reduced leach residence times and therefore reduced tank capacity requirements, while increasing gold recoveries.

“The latest metallurgical results support the likelihood of achieving high recoveries with the potential use of standard CIL processing commonly used in the Western Australian gold industry, and also support the use of the lower capital cost option of Heap Leach, both of which will be studied further,” Gold Road Resources chairman Ian Murray said in the company’s announcement to the Australian Securities Exchange.

“These results, combined with the current resource drilling program, should allow us to continue to rapidly add value to the Gruyere project.”

Further testwork recommended by the February report includes grind tests at 150 micron to investigate recovery behaviour at even coarser grind than has been tested to date.

Other testing will involve column tests for heap leach testing to confirm initial intermittent bottle roll test results as well as comminution testing to facilitate grinding mill calculations.

Email: perth@goldroad.com.au

Website:  www.goldroad.com.au

Virax signs licence option with Moffitt Center

THE ROADHOUSE PHARMACY: Virax Holdings (ASX: VHL) has entered into an Option Agreement with the Moffitt Cancer Center and Research Institute in Tampa, Florida to license novel technology which allows for the selection of breast and other cancer patients that are likely to respond to Virax’s GGTI-2418.

GGTI-2418 works in conjunction with p27, which in normal cells plays a key role in very tightly regulating cell division.

Virax explained that in some cancer types, including breast cancer, p27 is expressed at very low levels and this contributes to the uncontrolled cell division, a major hallmark of cancer.

The lower the p27 levels, the worse are the patient outcomes.

GGTI-2418 increases the levels of p27 in the nucleus and, by doing so, kills tumor cells.

Virax claims patients whose tumors express very low levels of p27 and where GGTI-2418 increases these levels are more likely to respond to Virax’s GGTI-2418.

GGTI-2418 is a small molecule which inhibits geranylgeranyltransferase I.

Virax said GGTI-2418 was found to induce apoptosis and inhibit growth in breast cancer as it is thought to inhibit the geranylgeranylation of the protein Rho, thereby inactivating the protein.

In cancer cells, overactive Rho is thought to lower the levels of the p27 which normally acts as a brake on the cell cycle.

GGTI-2418 can therefore inactivate Rho leading to higher levels of nuclear p27 stopping aberrant growth.

“We plan to add this exciting tool to our portfolio, shortly after completion of the licensing of the Yale oncology assets announced last month, and which goes to shareholders for approval on 9th May,” Virax executive chairman Dr Wayne Millen said in the company’s announcement to the Australian Securities Exchange.

“The p27 technology will allow us precision in determining those patients who are more likely to respond to GGTI-2418 therapy.”

Virax said the technology presents a method of using baseline nuclear p27 expression level in the breast tumors as a biomarker for response to GGTI-2418 treatment.

The data suggests that breast tumors with low baseline nuclear p27 expression where GGTI-2418 increases these levels are likely to benefit from the GGTI-2418 treatment.

Website: www.virax.com.au

SomnoMed open for business in Finland

THE ROADHOUSE PHARMACY: SomnoMed (ASX: SOM) has announced the commencement of operations in Finland.

The company regards Finland as last remaining market in Scandinavia after developing its market position in Sweden over the last five years and taking a leadership position in the custom made quality oral appliance market, SomnoMed entered Norway one year ago and started to offer SomnnoDent® products in Denmark in late 2013.

SomnoMed announced it has entered into an agreement with a Helsinki based orthodontic laboratory to provide logistic and repair services.

The company has also recruited a country sales & marketing manager, with extensive industry experience as former sales manager of companies, such as Resmed and Fisher & Paykel in Finland.

“With the entry of SomnoMed in Finland we now cover all of Scandinavia with our own, dedicated sales and marketing team,” SomnoMed executive chairman Dr. Peter Neustadt said in the company’s announcement to the Australian Securities Exchange.

“Scandinavia is a well advanced market when it comes to COAT™ treatment, which is well accepted as an alternative to CPAP.

“We see excellent growth potential in the years ahead.

“Finland is one of the six remaining markets in Europe SomnoMed intends to enter and establish its own operation during the course of this year, so as to achieve full coverage of the developed Northern, Central and Southern regions of Europe.”

Website: www.somnomed.com.au

Admedus enjoys CardioCel six year celebration

THE ROADHOUSE PHARMACY: Admedus (ASX: AHZ) announced that six years post implantation CardioCel® continues to show no level of calcification or any other issues.

The company said the first patient from the Phase II study has had their six year follow up with results demonstrating there is still no detectable calcification of CardioCel® with no ‘re-do’ surgery required and no other issues.

The patient was initially implanted at three weeks of age and has now reached their sixth birthday with no implant issues.

“This is great progress for patients in not having to have additional surgeries and it represents huge potential for the future treatment of congenital heart disease and other cardiac defects,” Admedus CEO Lee Rodne said in the company’s announcement to the Australian Securities Exchange.

Admedus declared all other patients in the study have also continued to show no signs of calcification or follow up surgeries after three to five years.

The company anticipates continued data from the ongoing monitoring of these patients.

“We have always believed that CardioCel® has enormous potential in the future of cardiac surgery and this data highlights the longer term benefits of using CardioCel® and its superiority over alternatives,” Rodne said.

Patients from the Phase II study are examined for calcification and overall patient health annually.

Earlier this year Admedus received FDA clearance for CardioCel® and last year CardioCel® was approved in Europe under a CE Mark.

Email: info.au@admedus.com

Website: www.admedus.com

What the Brokers Say

WHAT THE BROKERS SAY: Interesting news and views from across the Resource Analyst universe.

www.breakawayresearch.com

King Island Scheelite (ASX: KIS)

King Island Scheelite is looking to fast track its King Island Scheelite project, with an aim to commence production possibly as soon as early 2016.

This historical high-grade producer still has significant open cut and underground resources, at grades significantly higher than ASX-listed peers.

The key to the King Island project is its grade – an average LOM feed grade of approx. 0.83 per cent tungsten contributes to a potentially robust operation.

There is also good exploration potential on the flanks of the mineralising intrusives.

The company share register is dominated by key stakeholders in the project (including the directors), and hence we see significant motivation to generate value in the company.

King Island Scheelite has completed a Definitive Feasibility Study and supplementary studies for re-opening the historic King Island Scheelite Mine located on King Island, in Bass Strait, Australia.

Current open cut and underground hard rock resources are in the order of 6.4 million tonnes at 1.2 per cent tungsten (10.6 million tonnes at 0.93 per cent tungsten using a lower cut-off), with additional low grade resources in the tailings dam.

The company is considering a staged open cut and underground development, and is looking to fast track development of the project.

Little needs to be done with regards to permitting by virtue of approvals being in place from previous work, with this development not proceeding due to circumstances largely out of the company’s control.

King Island Scheelite is currently scoping a combined open cut, limited tailings retreatment and underground operation at its 100 per cent-held King Island Scheelite project, with the potential to produce up to 36,000 tonnes of tungsten over a 13 year mine life.

This is in effect a hybrid of two previous studies – a 2006 DFS that was based on a large open cut at the historic Dolphin Mine, and a 2012 study based on tailings retreatment followed by underground mining at Dolphin and Bold Head.

www.psl.com.au

Centrex Metals Limited (CXM)

Centrex Metals has successfully implemented a business strategy of attracting foreign investment to develop early stage exploration assets in Australia.

To date the company has secured the support of two major Chinese steel producers for its iron ore assets in South Australia and one major Chinese partner for a base metals project in New South Wales.

With $35 million in cash, CXM is well positioned to maintain these assets and advance its new metals portfolio which will provide short, medium and long term value to the company.

CXM has been focused on the development of its iron ore assets and infrastructure on the Eyre Peninsula in South Australia since 2001.

In 2010 it successfully created joint ventures with major Chinese steel producers, Wuhan Iron & Steel (WISCO) and Baotou Iron & Steel (Baotou), to fund the development of two magnetite projects.

CXM also owns 100 per cent of a small hematite DSO operation and another magnetite project which has had some encouraging exploration results recently, which could lead to another Joint Venture agreement.

These magnetite projects are located between 40km and 100km via slurry pipeline from ports and
CXM has identified and developed a conditionally approved port solution at Port Spencer.

The projects are also located in an area close to large regional centres and relatively well endowed with infrastructure including roads and national grid power.

CXM has built a portfolio of early stage exploration tenements in the Lachlan Fold Belt, NSW.

The portfolio is prospective for base and precious metals with historical mineralisation evident at all prospects.

CXM will endeavour to develop these projects in a similar fashion as it has developed its iron ore holdings.

This will be done through conservative exploration expenditure to develop each tenement, prior to seeking foreign investment partner.

CXM has successfully executed this strategy with the Goulburn zinc-lead project by executing a Joint Venture agreement with the Shandong 5th Geo-Mineral Prospecting Institute.

All Joint Ventures are structured to have minimal impact on the company’s cash reserves and financial structure.

As the projects develop, CXM, with its JV partners, will look to raise the require capital at the project level.

This should ultimately provide CXM with a portfolio of minority holdings in projects producing a number of commodities around Australia.

Over the next 12 months Patersons envisages a number of significant catalysts for CXM including 1) Chinese approval and commencement of drilling on the Goulburn JV tenements; 2) Exploration success at Woolgarlo and Gundaroo; 3) Resource definition and JV agreement for Kimba Gap; 4) Baotou increasing its interest in the Bungalow JV to 50 per cent and investing the additional $16 million.

Disclaimer: The above is intended as a guide only. The Roadhouse accepts no responsibility for investments made from this advice, successful or otherwise.

The views, opinions or recommendations of this article do not in any way reflect the views, opinions, recommendations, of The Resources Roadhouse.

The Roadhouse makes no representation or warranty with respect to the accuracy, completeness or currency of the content. The content is for educational purposes only and does not constitute financial advice. Independent advice should be obtained from an Australian financial services licensee before making investment decisions.